Watson To Discontinue Production At Puerto Rico Plant
This article was originally published in The Pink Sheet Daily
Executive Summary
Watson plans to phase-out production at its Humacao, Puerto Rico manufacturing facility over the next 18 to 24 months
|
Watson plans to phase-out production at its Humacao, Puerto Rico manufacturing facility over the next 18 to 24 months. The closure is due to overcapacity at the company's solid dosage manufacturing facilities, Watson said Oct. 11. Watson acquired the Puerto Rico facility in 2000 as part of its purchase of Schein Pharmaceutical. Watson plans to transfer manufacturing operations for the 16 products produced at the Humacao facility to its other two solid dosage manufacturing sites in Corona, Calif. and Carmel, N.Y. "Over the last several years, Watson has made significant improvements and enhancements to its solid dosage manufacturing facilities, creating the opportunity for its Carmel, N.Y. and Corona, Calif. sites to absorb additional production volume," the company said. The Corona facility has been operating under an FDA consent decree since 2002. A 2004 FDA inspection of the site prompted a '483 report, but the plant passed its most recent inspection in April (1 (Also see "Watson Responds To FDA-483 For Corona, Calif. Facility" - Pink Sheet, 26 Aug, 2004.)). - Brian Marson |